This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Supernus Pharmaceuticals Reports Second Quarter 2013 Financial Results

ROCKVILLE, Md., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported financial results for the three and six months ended June 30, 2013, and provided an update on key accomplishments to date.

"Oxtellar XR TM continues to impress us with its clinical performance in the market. Prescribers are highly satisfied with the product and patients appreciate its key benefits. We are pleased with continued growth in the prescriber base and monthly prescriptions as we head into the middle of the third quarter. We also remain excited about our preparations for the upcoming launch of Trokendi XR TM later this quarter," said Jack Khattar, President and CEO of Supernus Pharmaceuticals, Inc.

Second Quarter 2013 Financial Results

  • Our net product revenue of $0.2 million for the three months ended June 30, 2013 is comprised of 529 Oxtellar XR TM prescriptions filled at the pharmacy level during the first quarter of 2013. Consistent with industry norm, the net price of Oxtellar XR TM reflects deductions for one-time discounts paid to wholesalers to initially stock Oxtellar XR TM, as well as customary payer rebates, allowances, and the cost of a co-payment rebate program.
  • Our product gross margin on net product revenue was 97%. This number is affected by pre-approval and start-up activities.
  • Research and development (R&D) expense for the second quarter declined from $4.7 million in 2012 to $3.5 million in 2013, primarily because our Phase IIb study for SPN-810 was completed in 2012.
  • Selling, general and administrative (SG&A) expense for the second quarter increased from $4.6 million in 2012 to $12.2 million in 2013. This increase is attributable to increased sales and marketing costs associated with the commercial launch of Oxtellar XR TM and the planned launch of Trokendi XR TM in the third quarter of 2013.
  • Related to our $90 million convertible notes offering, the Company recorded a non-cash charge of $8.6 million due to changes in fair value of derivative liabilities.
  • Net loss applicable to common shareholders for second quarter 2013 was $27.4 million or $0.89 per common share (based on 30.9 million weighted average shares outstanding), compared to a net loss of $10.3 million in the second quarter of 2012 or $0.61 per common share (based on 16.8 million weighted average shares outstanding).
  • Excluding the charges for changes in fair value of derivative liabilities of $8.6 million and loss on extinguishment of debt of $1.2 million, non-GAAP net loss for the second quarter 2013 was $17.6 million.

Six Months Ended June 30, 2013 Financial Results

  • Our net product revenue of $0.2 million for the six months ended June 30, 2013 is comprised of 529 Oxtellar XR TM prescriptions filled at the pharmacy level during the first quarter of 2013. Consistent with industry norm, the net price of Oxtellar XR TM reflects deductions for one-time discounts paid to wholesalers to initially stock Oxtellar XR TM, as well as customary payer rebates, allowances, and the cost of a co-payment rebate program.
  • Our product gross margin on net product revenue was 97%. This number is affected by pre-approval and start-up activities. 
  • R&D expense for the first half of 2013 was $8.1 million compared with $10.1 million in 2012. The decrease was primarily attributable to the completion of our Phase IIb study for SPN-810 in 2012.
  • SG&A expense for the first half of 2013 was $25.7 million compared with $7.4 million in 2012, increasing year over year due to hiring of our sales force as well as costs associated with the commercial launch of Oxtellar XR TM and the planned launch of Trokendi XR TM in the third quarter of 2013.
  • Net loss applicable to common shareholders for the first half of 2013 was $45.8 million or $1.48 per common share (based on 30.9 million weighted average shares outstanding), compared to $20.4 million or $2.21 per common share (based on 9.2 million weighted average shares outstanding in 2012).
  • Excluding the charges for changes in fair value of derivative liabilities of $8.5 million and loss on extinguishment of debt of $1.2 million, non-GAAP net loss for the six months ended June 30, 2013 was $36.1 million.

Financial Update

  • Our anticipated cash burn for 2013 continues to be estimated to be in the range of $85 million to $95 million. Based on our current plans, we continue to anticipate that our current cash, cash equivalents, unrestricted marketable securities and long term investments as of June 30, 2013 should be sufficient to fund operations through the end of 2014, by which time we project to be cash flow break even.
  • For the six months ended June 30, 2013, the net value of Oxtellar XR TM sold to wholesalers was $4.2 million. Consequently, in addition to $0.2 million in recognized revenue, we recorded $4.0 million of deferred revenue at June 30 (i.e., $4.8 million gross deferred revenue net of $0.8 million in estimated costs and allowances).
  • Cash collections from the sale of Oxtellar XR TM in the quarter ended June 30, 2013 were approximately $1.8 million, with a total of $4.4 million collected from wholesalers through the first six months. Accounts receivable as of June 30, 2013 were approximately $0.5 million.

Liquidity and Capital Resources

  • Cash, cash equivalents and marketable securities increased from $88.5 million at December 31, 2012 to $118.7 million at June 30, 2013. On May 3, 2013, the Company closed on an offering of $90 million in Convertible Senior Secured Notes ("Convertible Notes") due 2019. Coincident with the closing, the Company retired its venture debt facility in its entirety. Net proceeds, post debt retirement, were approximately $67 million.

Oxtellar XR Launch Update

  • The launch of Oxtellar XR TMcontinued to progress well during the 2nd Quarter. Oxtellar XR TM prescriptions, as reported by IMS, increased from 529 in the 1st Quarter to 3,648 prescriptions in the 2nd Quarter. Over 1,100 target physicians have prescribed Oxtellar XR TM since launch, a substantial increase over the 450 target physicians prescribing Oxtellar XR TM we last reported.
  • Based on IMS data, for the week ending the 2 nd of August, Oxtellar XR TM achieved a conversion share of the addressable oxcarbazepine market of approximately 1.34%, a significant increase over the 0.58% conversion share we reported during our 1st Quarter Oxtellar XR TM Launch Update. 
  • For the week ending July 19, among the target prescribers where our sales force has been concentrating its efforts, the conversion market share is 1.9%. In addition, for the same week, the conversion market share of Oxtellar XR TM is approximately 3.5% and 5.4% among the top target physicians per territory that have been called on 7 - 12 times and 13 – 18 times since launch, respectively. We believe this is a significant share at this stage in the launch showing a strong correlation between call frequency and market share levels, and confirming that Oxtellar XR TM is promotion responsive.
  • Our sales force continues to be successful in increasing the number of calls on target physicians to an average of 1,500 calls per week compared to a previous high of 1,200 calls per week on average, as reported in the 1st Quarter Oxtellar XR TM Launch Update.
  • Feedback from the field, supported by results from a qualitative market research study, confirms that prescribers of Oxtellar XR TM continue to be extremely pleased with what their patients are reporting regarding the efficacy and tolerability profile of Oxtellar XR TM. The top reasons physicians report for choosing Oxtellar XR TM are reduction in adverse events, once-a- day dosing and the ability to get patients on a higher dose of oxcarbazepine when needed.
  • Oxtellar XR TMhas continued to achieve strong coverage in managed care with 142 million lives covered, 127million on the commercial side and 15 million on Medicaid.
  • Comparing the early stage performance of Oxtellar XR TM to other extended release anti-epileptic products that have been launched, Oxtellar XR TM seems to be continuing to track in line with the weekly market share trends of Carbatrol ®. As a reference, Carbatrol ® achieved a 1.8% market share of the carbamazepine market in its first 12 months on the market increasing to 4.7% in the second full year after launch.
  • In summary, our sales force is executing well in the field, and Oxtellar XR TM continues to be received well by physicians and patients. This results in significant growth in number of prescribing physicians and prescriptions.

Pipeline Update

Regarding Trokendi XR TM, we continue to expect receiving final approval and commercially launching Trokendi XR TM in the third quarter of 2013. 

Finally, regarding the rest of the pipeline, we continue to progress SPN 810 with the goal of having a meeting with the FDA by year end to discuss with them our plans for later stage clinical studies and to progress SPN 812 with the development of a novel once daily formulation to be used later in a phase IIb study.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,910.53 -4.54 -0.03%
S&P 500 1,962.15 -2.53 -0.13%
NASDAQ 4,401.0090 +4.8050 0.11%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs